Ivonescimab’s progression-free survival data in non-small cell lung cancer bode well for an upcoming overall survival readout ...

Ivonescimab’s progression-free survival data bode well for an upcoming overall survival readout, according to Truist analysts ...

Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...

Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...

Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the ...

Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...

After a chaotic year that has seen the attrition of over half the FDA’s senior leadership, many of these individuals have ...

Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...

CMS Administrator Mehmet Oz clarified that a deal has not yet been sealed with the manufacturer of semaglutide, Novo Nordisk, ...

In a volatile industry, staying put might seem like a smart bet, but job hugging can quietly erode your visibility, growth ...